Figure 1.
Figure 1. 17β-E2–dependent Src kinase activation. (A) Gel-filtered platelets were incubated with buffer or with increasing concentrations of 17β-E2 (E2: 1, 10, 100, and 1000 nM) for 30 seconds. (B) Gel-filtered platelets were incubated with buffer or with 100 nM 17β-E2 (E2) for increasing times (0, 30, 60, and 180 seconds.) Platelets were lysed, and identical aliquots from each sample were simultaneously analyzed by immunoblotting with specific antibodies against pSrc-Tyr416 (Src PY 416) or against Src. Platelet stimulation with 100 nM 17β-E2 for 30 seconds was performed in the presence of 10 μM ICI 182 780, an ER antagonist. Results are representative of those of several different experiments.

17β-E2–dependent Src kinase activation. (A) Gel-filtered platelets were incubated with buffer or with increasing concentrations of 17β-E2 (E2: 1, 10, 100, and 1000 nM) for 30 seconds. (B) Gel-filtered platelets were incubated with buffer or with 100 nM 17β-E2 (E2) for increasing times (0, 30, 60, and 180 seconds.) Platelets were lysed, and identical aliquots from each sample were simultaneously analyzed by immunoblotting with specific antibodies against pSrc-Tyr416 (Src PY 416) or against Src. Platelet stimulation with 100 nM 17β-E2 for 30 seconds was performed in the presence of 10 μM ICI 182 780, an ER antagonist. Results are representative of those of several different experiments.

Close Modal

or Create an Account

Close Modal
Close Modal